# KEYNOTE-775 / Study 309

Source: https://onco.cc/trials/keynote-775/  
OnCo record `keynote-775` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A pill that blocks tumour blood vessels plus immunotherapy extended survival after chemotherapy, including in tumours that immunotherapy alone does not touch.

## Summary

OS 18.3 vs 11.4 months in all comers (HR 0.62) and 17.4 vs 12.0 months in pMMR (HR 0.68); PFS 7.2 vs 3.8 months (NEJM 2022). Full approval 2021 for pMMR disease after platinum. Toxicity is substantial: hypertension, hypothyroidism, diarrhoea, and dose reductions in two-thirds of patients. Now largely used after first-line chemo-immunotherapy.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT03517449
- Phase: 3
- Setting: Advanced endometrial cancer after platinum: lenvatinib + pembrolizumab vs doxorubicin or weekly paclitaxel
- Sponsor: Eisai / Merck
- Enrolled: 827
- Result: OS 18.3 vs 11.4 months (HR 0.62).
- Outcomes: Overall survival (all comers): Lenvatinib + pembrolizumab 18.3 months vs Chemotherapy 11.4 months, HR 0.62; Progression-free survival (all comers): Lenvatinib + pembrolizumab 7.2 months vs Chemotherapy 3.8 months, HR 0.56

## Sources

- ClinicalTrials.gov NCT03517449: https://clinicaltrials.gov/study/NCT03517449
- NEJM 2022: https://www.nejm.org/doi/full/10.1056/NEJMoa2108330

## Connected records

- cancers: [Advanced or recurrent endometrial cancer](https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Endometrial cancer with no specific molecular profile](https://onco.cc/cancers/endometrial-nsmp/), [p53-abnormal endometrial cancer, including uterine serous carcinoma](https://onco.cc/cancers/endometrial-p53-abnormal/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- drugs: [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Eisai](https://onco.cc/companies/eisai/)
- pairings: [Lenvatinib + pembrolizumab (pMMR endometrial cancer after platinum)](https://onco.cc/pairings/lenvatinib-plus-pembrolizumab/)
- key papers: [KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer](https://onco.cc/key-papers/paper-keynote-775-nejm-2022/)

---
JSON: https://onco.cc/api/v1/entities/keynote-775.json